Business Context and Reporting Period
Company: E. I. du Pont de Nemours and Company (DuPont)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 1994
Reporting Date: November 10, 1994
DuPont reported record earnings for the third quarter and the first nine months of 1994. Performance was driven by higher sales volumes, reduced fixed costs, and strong results across chemical and specialties segments, alongside continued performance in the Petroleum segment despite a challenging industry environment.
Key Financial Metrics
| Metric (Dollars in Millions) | Q3 1994 | Q3 1993 | 9 Months 1994 | 9 Months 1993 |
|---|---|---|---|---|
| Sales | $9,845 | $9,231 | $29,196 | $27,847 |
| Net Income | $647 | $(680) | $2,081 | $329 |
| Earnings Per Share | $0.95 | $(1.01) | $3.05 | $0.48 |
| Cash Provided by Operations | N/A | N/A | $4,392 | $3,724 |
| Capital Expenditures | N/A | N/A | $(2,003) | $(2,634) |
| Total Debt (Short + Long Term) | $8,598 | N/A | $8,598 | N/A |
| Cash and Equivalents | $2,402 | N/A | $2,402 | N/A |
Note: Q3 1993 results included a $1.8 billion pretax restructuring charge and a $265 million tax benefit. Q3 1994 included offsetting nonrecurring items with no net effect on EPS.
Material Changes vs. Prior Period
- Profitability Surge: Net income swung from a $680 million loss in Q3 1993 to a $647 million profit in Q3 1994. Adjusted earnings (excluding nonrecurring items) increased 86% year-over-year for the quarter and 58% for the nine-month period.
- Revenue Growth: Sales increased 7% in Q3 and 5% year-to-date, driven primarily by volume growth in Chemicals, Fibers, and Polymers segments.
- Segment Performance:
- Chemicals: Earnings up 126% due to improved specialty chemical results.
- Fibers: Earnings up 50% driven by nylon, nonwovens, and Lycra spandex.
- Polymers: Earnings up 149% with strong performance in engineering and packaging polymers.
- Petroleum: Earnings down 5% due to lower upstream earnings (gas volumes, exploration costs), partially offset by higher downstream margins.
- Diversified: Earnings up significantly due to coal recovery and crop protection chemicals.
- Liquidity Improvement: Cash and cash equivalents increased by $1.2 billion to $2.4 billion. The debt ratio (total debt to total capitalization) improved to 40.4% from 45.0% at year-end 1993.
Outlook, Risks, and Contingencies
Management Commentary and Guidance
- Capital Expenditures: Planned reductions in capex for chemicals and specialties. Full-year capex is projected to be under $3.0 billion, down from a budget of $3.4 billion.
- Restructuring: The $1.8 billion restructuring charge from Q3 1993 is substantially complete regarding asset write-downs. A liability of approximately $395 million remains for employee separation costs.
Risks and Legal Proceedings
- Benlate Litigation: Over 550 lawsuits filed by growers alleging crop damage from "Benlate" DF 50 fungicide. DuPont maintains the product did not cause damage. Recent jury verdicts in Florida and Alabama found no defect. Settlements have been reached for blocks of cases.
- Polybutylene Plumbing: Approximately 100 lawsuits alleging damages from leaks. A nationwide class action is pending in Texas; certification could lead to a settlement fund of up to $750 million, though DuPont expects its share to be modest.
- Environmental Penalties:
- EPA (Sabine River Works): Settled for a $516,430 penalty plus $3.2 million in environmental projects.
- EPA (Benomyl/Atrazine): Settled for $1 million.
- EPA (Triazine Herbicides): Facing a proposed $1.9 million penalty for label non-compliance; DuPont plans to contest.
- State Actions: Various smaller penalties settled or pending in Texas, Colorado, and Delaware.
Investor Verification Checklist
- Nonrecurring Items: Verify the specific composition of the "offsetting nonrecurring items" in Q3 1994 that neutralized the impact of tax benefits and charges on EPS.
- Petroleum Exposure: Assess the sensitivity of the Petroleum segment's earnings to future fluctuations in crude oil and natural gas prices, given the 23% drop in upstream earnings.
- Legal Accruals: Review the adequacy of accruals for the Benlate and Polybutylene litigation, particularly regarding the potential $750 million class action settlement fund.
- Capex Execution: Monitor whether the projected reduction in capital expenditures to under $3.0 billion is achieved without impacting long-term growth capacity.
- Debt Reduction: Confirm the trajectory of the $0.8 billion reduction in consolidated borrowings reported for the nine-month period.